Is Fennec Pharmaceuticals Stock a Good Investment?
Fennec Pharmaceuticals Investment Advice | FENC |
- Examine Fennec Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Fennec Pharmaceuticals' leadership team and their track record. Good management can help Fennec Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Fennec Pharmaceuticals' business and its evolving consumer preferences.
- Compare Fennec Pharmaceuticals' performance and market position to its competitors. Analyze how Fennec Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Fennec Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Fennec Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Fennec Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Fennec Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Fennec Pharmaceuticals Stock
Researching Fennec Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.04. Fennec Pharmaceuticals had not issued any dividends in recent years. The entity had 1:3 split on the 5th of September 2014.
To determine if Fennec Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fennec Pharmaceuticals' research are outlined below:
| Fennec Pharmaceuticals generated a negative expected return over the last 90 days | |
| Fennec Pharmaceuticals has high historical volatility and very poor performance | |
| Fennec Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 21.25 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 1.45 M. | |
| Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57. | |
| Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 |
Fennec Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fennec Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fennec Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Fennec Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Fennec Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-05-09 | 2019-03-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2020-08-05 | 2020-06-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2018-08-13 | 2018-06-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2018-05-14 | 2018-03-31 | -0.12 | -0.09 | 0.03 | 25 | ||
2021-08-10 | 2021-06-30 | -0.19 | -0.15 | 0.04 | 21 | ||
2023-11-06 | 2023-09-30 | -0.12 | -0.07 | 0.05 | 41 | ||
2023-08-03 | 2023-06-30 | -0.16 | -0.21 | -0.05 | 31 | ||
2022-08-12 | 2022-06-30 | -0.14 | -0.19 | -0.05 | 35 |
Know Fennec Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fennec Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fennec Pharmaceuticals backward and forwards among themselves. Fennec Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Fennec Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 204.2 K | Northern Trust Corp | 2024-09-30 | 139.7 K | Winton Capital Group Ltd | 2024-09-30 | 71.7 K | Millennium Management Llc | 2024-06-30 | 69.3 K | Bank Of New York Mellon Corp | 2024-06-30 | 68.7 K | Cibc World Markets Inc. | 2024-06-30 | 56.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 55.5 K | Acadian Asset Management Llc | 2024-06-30 | 53.3 K | Advantage Alpha Capital Partners, Lp | 2024-09-30 | 52.9 K | Southpoint Capital Advisors Lp | 2024-06-30 | 4.1 M | Sonic Gp Llc | 2024-09-30 | 2.4 M |
Fennec Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 129.48 M.Market Cap |
|
Fennec Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.66) | (0.63) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | 1.38 | 1.45 |
Determining Fennec Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Fennec Pharmaceuticals is a good buy. For example, gross profit margin measures Fennec Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fennec Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Fennec Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fennec Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fennec Pharmaceuticals' management manipulating its earnings.
Evaluate Fennec Pharmaceuticals' management efficiency
Fennec Pharmaceuticals has return on total asset (ROA) of 0.027 % which means that it generated a profit of $0.027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.45, whereas Return On Tangible Assets are forecasted to decline to (0.63). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.21, whereas Total Assets are forecasted to decline to about 16.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.44) | (0.42) | |
| Tangible Book Value Per Share | (0.44) | (0.42) | |
| Enterprise Value Over EBITDA | (25.55) | (26.82) | |
| Price Book Value Ratio | (25.65) | (24.37) | |
| Enterprise Value Multiple | (25.55) | (26.82) | |
| Price Fair Value | (25.65) | (24.37) | |
| Enterprise Value | 88.5 M | 92.9 M |
Leadership effectiveness at Fennec Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.267 |
Basic technical analysis of Fennec Stock
As of the 22nd of November, Fennec Pharmaceuticals shows the Standard Deviation of 3.96, variance of 15.67, and Mean Deviation of 2.93. Fennec Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fennec Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fennec Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fennec Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fennec Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fennec Pharmaceuticals' Outstanding Corporate Bonds
Fennec Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fennec Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fennec bonds can be classified according to their maturity, which is the date when Fennec Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Fennec Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Fennec Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 2.93 | |||
| Coefficient Of Variation | (2,091) | |||
| Standard Deviation | 3.96 | |||
| Variance | 15.67 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 23.48 | |||
| Value At Risk | (6.68) | |||
| Potential Upside | 5.98 | |||
| Skewness | 0.0418 | |||
| Kurtosis | 1.43 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 2.93 | |||
| Coefficient Of Variation | (2,091) | |||
| Standard Deviation | 3.96 | |||
| Variance | 15.67 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 23.48 | |||
| Value At Risk | (6.68) | |||
| Potential Upside | 5.98 | |||
| Skewness | 0.0418 | |||
| Kurtosis | 1.43 |
Consider Fennec Pharmaceuticals' intraday indicators
Fennec Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fennec Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 58294.7 | |||
| Daily Balance Of Power | 0.6897 | |||
| Rate Of Daily Change | 1.13 | |||
| Day Median Price | 5.12 | |||
| Day Typical Price | 5.18 | |||
| Price Action Indicator | 0.51 | |||
| Period Momentum Indicator | 0.6 |
Fennec Pharmaceuticals Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of November 2024 Other Reports | ViewVerify | |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Fennec Stock media impact
Far too much social signal, news, headlines, and media speculation about Fennec Pharmaceuticals that are available to investors today. That information is available publicly through Fennec media outlets and privately through word of mouth or via Fennec internal channels. However, regardless of the origin, that massive amount of Fennec data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fennec Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fennec Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fennec Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fennec Pharmaceuticals alpha.
Fennec Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Fennec Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fennec Pharmaceuticals Corporate Management
| Mark Meier | VP Commercial | Profile | |
| Christiana MBA | Chief Officer | Profile | |
| Mark Gowland | Controller | Profile | |
| Terry Evans | Chief Officer | Profile | |
| Robert Andrade | Chief Officer | Profile | |
| Dr MS | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 1.814 | Quarterly Revenue Growth 0.07 | Return On Assets 0.027 | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Fennec Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.